Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,693,789
  • Shares Outstanding, K 105,188
  • Annual Sales, $ 675,040 K
  • Annual Income, $ 141,210 K
  • EBIT $ 66 M
  • EBITDA $ 56 M
  • 60-Month Beta 0.20
  • Price/Sales 13.03
  • Price/Cash Flow 67.30
  • Price/Book 13.91

Options Overview Details

View History
  • Implied Volatility 114.42% (+13.17%)
  • Historical Volatility 37.25%
  • IV Percentile 95%
  • IV Rank 76.01%
  • IV High 138.94% on 12/15/25
  • IV Low 36.71% on 08/28/25
  • Expected Move (DTE 20) 16.50 (19.96%)
  • Put/Call Vol Ratio 1.33
  • Today's Volume 5,464
  • Volume Avg (30-Day) 2,043
  • Put/Call OI Ratio 1.71
  • Today's Open Interest 45,436
  • Open Int (30-Day) 41,792
  • Expected Range 66.15 to 99.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.30
  • Low Estimate 0.18
  • Prior Year 0.26
  • Growth Rate Est. (year over year) +3.85%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.55 +6.57%
on 12/01/25
89.00 -7.13%
on 12/15/25
+2.85 (+3.57%)
since 11/26/25
3-Month
67.00 +23.36%
on 11/05/25
91.00 -9.18%
on 10/08/25
-1.22 (-1.45%)
since 09/26/25
52-Week
49.00 +68.67%
on 01/13/25
117.33 -29.56%
on 03/31/25
+29.02 (+54.11%)
since 12/26/24

Most Recent Stories

More News
Why Corcept (CORT) Stock Is Trading Lower Today

Why Corcept (CORT) Stock Is Trading Lower Today

CORT : 82.65 (-1.12%)
Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?

Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?

CORT : 82.65 (-1.12%)
Why Corcept (CORT) Stock Is Down Today

Why Corcept (CORT) Stock Is Down Today

CORT : 82.65 (-1.12%)
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know

CORT : 82.65 (-1.12%)
ELAN : 22.60 (+0.98%)
LMAT : 83.78 (-0.66%)
PEN : 316.97 (+0.35%)
RMD : 244.76 (+0.13%)
1 Growth Stock with Explosive Upside and 2 We Brush Off

1 Growth Stock with Explosive Upside and 2 We Brush Off

CORT : 82.65 (-1.12%)
RXO : 12.71 (-0.16%)
UMBF : 118.90 (unch)
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)

Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)

CORT : 82.65 (-1.12%)
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know

ENOV : 27.39 (+1.97%)
CORT : 82.65 (-1.12%)
LNTH : 66.71 (+0.04%)
EVH : 4.12 (-0.24%)
RGEN : 166.21 (+0.33%)
The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call

The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call

CORT : 82.65 (-1.12%)
CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook

CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook

CORT : 82.65 (-1.12%)
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings

Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings

CORT : 82.65 (-1.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Corcept is focused on the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncology disorders which are associated with the activity of the hormone cortisol, also known as the stress hormone. Corcept's only marketed drug, Korlym (mifepristone),...

See More

Key Turning Points

3rd Resistance Point 85.09
2nd Resistance Point 84.40
1st Resistance Point 83.52
Last Price 82.65
1st Support Level 81.95
2nd Support Level 81.26
3rd Support Level 80.39

See More

52-Week High 117.33
Fibonacci 61.8% 91.23
Fibonacci 50% 83.17
Last Price 82.65
Fibonacci 38.2% 75.10
52-Week Low 49.00

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar